Chemomab Therapeutics Ltd. has announced the presentation of positive Phase 2 clinical data for their investigational drug, nebokitug, at BSG Live'25, the annual scientific meeting of the British Society for Gastroenterology in Glasgow, UK. The data, from the SPRING trial, indicates that nebokitug is well-tolerated and associated with significant improvements in fibrotic and inflammatory biomarkers in patients with primary sclerosing cholangitis $(PSC.AU)$. These improvements suggest a potential slowing of disease progression. The findings support the advancement of nebokitug to a Phase 3 trial, positioning it as a potential first-in-class treatment for PSC. The results were presented by Professor Douglas Thorburn, the Principal Investigator of the SPRING trial.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。